CHOSA Oncology, a prominent player in the oncology biotechnology sector, has announced compelling findings from its Phase III SPLENDOUR trial, assessing the efficacy of its Platin-DRP® biomarker in patients with advanced non-small cell lung cancer (NSCLC) undergoing platinum-based chemotherapy. The translational analysis, encompassing 82 patients, revealed that higher Platin-DRP® scores are significantly correlated with improved progression-free survival (PFS) and overall survival (OS).

The data, presented at the European Lung Cancer Congress (ELCC) 2026, underscore the potential of Platin-DRP® as a predictive biomarker for platinum sensitivity in NSCLC treatment. The analysis demonstrated that patients with higher DRP scores experienced a median overall survival of 16.9 months, compared to just 5.5 months for those with lower scores. This represents a clinically meaningful improvement, highlighting Platin-DRP®'s potential to guide treatment decisions in both clinical trials and practice.

Importantly, the study found no significant interaction between the type of platinum-based chemotherapy—cisplatin or carboplatin—and the DRP score, suggesting the biomarker's applicability across both agents. Despite the lack of association between DRP score and response rate, the strong correlation with survival outcomes positions Platin-DRP® as a valuable tool in the absence of other validated predictive biomarkers for platinum-based therapies.

CEO of CHOSA, Dr. Peter Buhl Jensen, expressed optimism about the findings, emphasizing the biomarker's potential to become an essential component in personalizing treatment strategies for lung cancer patients. The results bolster CHOSA's confidence in advancing towards regulatory approval and commercial development of Platin-DRP®.

Given the promising data and the crucial role of platinum compounds in NSCLC therapy, investors might consider holding CHOSA's stock as the company continues its path towards validation and potential market expansion. The ongoing research into Platin-DRP®'s role in combination with immunotherapy further adds to its potential market impact.